| | Conditions & Treatments | Diseases

Krabbe Disease: Understanding its Impact on the Nervous System

Krabbe disease (globoid cell leukodystrophy, GLD) is a rare, autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GALC gene (14q31), encoding galactocerebrosidase (galactosylceramidase). Incidence: ~1 in 100,000 live births.

Pathophysiology

Enzyme deficiency → accumulation of galactosylceramide (galactocerebroside) and its toxic metabolite psychosine (galactosylsphingosine).
Psychosine is cytotoxic to oligodendrocytes → demyelination of central and peripheral nervous systems.
Globoid cells (multinucleated macrophages laden with undigested lipid) infiltrate white matter — histologic hallmark.
Neuroinflammation: Microglial activation, cytokine storm, blood-brain barrier disruption.

Clinical Forms

Diagnosis

Enzyme assay: Low GALC activity in leukocytes or dried blood spots (newborn screening in some states/countries).
Genetic testing: Biallelic GALC variants (common 30-kb deletion in Europeans).
MRI: Symmetric T2 hyperintensity in corticospinal tracts, cerebellar white matter, corpus callosum, basal ganglia; later atrophy.
Nerve conduction: Demyelinating peripheral neuropathy.

Treatment

Hematopoietic stem cell transplantation (HSCT): Only disease-modifying therapy. Must be done pre-symptomatically (ideally <30 days for infantile) — preserves neurodevelopment. Post-symptomatic HSCT does not reverse CNS damage.
Supportive care: Anticonvulsants, tone management (baclofen, botulinum), nutrition (G-tube), respiratory support, physical/occupational therapy, palliative care.
Emerging: Gene therapy (AAV-GALC), substrate reduction, enzyme replacement (intrathecal) — clinical trials ongoing.

Newborn Screening Impact

Early identification via NBS enables pre-symptomatic HSCT — transforming outcomes for infantile Krabbe. As of 2024, ~10 US states screen; advocacy for universal panel inclusion continues.

Krabbe disease exemplifies the critical window for intervention in neurodegenerative disorders: treat before symptoms.

Diseases - Related Articles

Type	Onset	Features	Prognosis
Early-infantile (classic)	3–6 months	Irritability, stiffness, developmental arrest, feeding difficulties, hypertonia, seizures, optic atrophy, peripheral neuropathy. Rapid progression.	Death by age 2–3 without treatment
Late-infantile	6 months – 3 years	Similar but slower; ataxia, vision loss, spasticity.	Death in childhood
Juvenile	3–16 years	Gait disturbance, spastic paraparesis, vision loss, cognitive decline.	Variable; survival to adulthood possible
Adult-onset	>16 years	Progressive spastic paraparesis, neuropathy, cognitive impairment; often misdiagnosed as MS.	Slow progression; near-normal lifespan